PE20220426A1 - Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida - Google Patents

Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida

Info

Publication number
PE20220426A1
PE20220426A1 PE2021001920A PE2021001920A PE20220426A1 PE 20220426 A1 PE20220426 A1 PE 20220426A1 PE 2021001920 A PE2021001920 A PE 2021001920A PE 2021001920 A PE2021001920 A PE 2021001920A PE 20220426 A1 PE20220426 A1 PE 20220426A1
Authority
PE
Peru
Prior art keywords
compound
fluoroethyl
pyrazol
carboxamide
methyl
Prior art date
Application number
PE2021001920A
Other languages
English (en)
Inventor
Jean-Francois Tamby
Chun Yang
Timothy Carlson
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of PE20220426A1 publication Critical patent/PE20220426A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Esta referido a un metodo para tratar la disfuncion sistolica, el cual comprende la administracion oral al paciente del Compuesto I en una cantidad diaria total de 10-350 mg, en donde el Compuesto I es (R)-4-(1-((3-(difluorometil)-1-metil-1H-pirazol-4-il)sulfonil)-1- fluoroetil)-N-(isoxazol-3-il)piperidina-1-carboxamida. Este metodo se emplea en el tratamiento de un sindrome o trastorno seleccionado del grupo que consiste en insuficiencia cardiaca, miocardiopatia, choque cardiogenico, una afeccion que se beneficia del soporte inotropico despues de una cirugia cardiaca, miocarditis, aterosclerosis, aldosteronismo secundario, infarto de miocardio, valvulopatia, hipertension sistemica, hipertension pulmonar o hipertension arterial pulmonar, remodelacion vascular perjudicial, edema pulmonar e insuficiencia respiratoria.
PE2021001920A 2019-05-19 2020-05-18 Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida PE20220426A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849936P 2019-05-19 2019-05-19
US201962852739P 2019-05-24 2019-05-24
PCT/US2020/033438 WO2020236736A1 (en) 2019-05-19 2020-05-18 Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Publications (1)

Publication Number Publication Date
PE20220426A1 true PE20220426A1 (es) 2022-03-29

Family

ID=70978663

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001920A PE20220426A1 (es) 2019-05-19 2020-05-18 Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida

Country Status (16)

Country Link
US (1) US20220265629A1 (es)
EP (1) EP3972597A1 (es)
JP (1) JP2022535195A (es)
KR (1) KR20220009440A (es)
CN (1) CN114173782A (es)
AU (1) AU2020279710A1 (es)
BR (1) BR112021023074A2 (es)
CA (1) CA3138080A1 (es)
CL (1) CL2021003045A1 (es)
CO (1) CO2021015505A2 (es)
IL (1) IL288051A (es)
MX (1) MX2021014109A (es)
PE (1) PE20220426A1 (es)
SG (1) SG11202112723PA (es)
TW (1) TW202110449A (es)
WO (1) WO2020236736A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7316449B2 (ja) * 2019-09-20 2023-07-27 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド 心不全治療におけるアンジオテンシンｉｉ受容体アンタゴニスト代謝産物とｎｅｐ阻害剤との複合体の使用
AU2021293817A1 (en) * 2020-06-15 2023-01-19 MyoKardia, Inc. Treatment of atrial dysfunction
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116082326A (zh) * 2022-12-16 2023-05-09 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
US20050250789A1 (en) * 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
LT3247707T (lt) * 2015-01-22 2023-08-25 MyoKardia, Inc. 4-metilsulfonilu pakeistieji piperidino karbamido junginiai, naudotini širdies sutrikimų, tokių kaip dilatacinė kardiomiopatija (dcm), gydymui

Also Published As

Publication number Publication date
WO2020236736A1 (en) 2020-11-26
CL2021003045A1 (es) 2022-07-08
CN114173782A (zh) 2022-03-11
CA3138080A1 (en) 2020-11-26
TW202110449A (zh) 2021-03-16
EP3972597A1 (en) 2022-03-30
IL288051A (en) 2022-01-01
MX2021014109A (es) 2021-12-10
AU2020279710A1 (en) 2021-12-23
CO2021015505A2 (es) 2021-12-10
US20220265629A1 (en) 2022-08-25
BR112021023074A2 (pt) 2022-03-29
SG11202112723PA (en) 2021-12-30
JP2022535195A (ja) 2022-08-05
KR20220009440A (ko) 2022-01-24

Similar Documents

Publication Publication Date Title
PE20220426A1 (es) Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida
Green et al. Management of acute right ventricular failure in the intensive care unit
Francis et al. Inotropes
Monaco et al. Management of challenging cardiopulmonary bypass separation
Imamura et al. Aortic insufficiency in patients with sustained left ventricular systolic dysfunction after axial flow assist device implantation
Delgado The pulmonary circulation in heart failure
Kodani et al. Target Intensity of Anticoagulation With Warfarin in Japanese Patients With Valvular Atrial Fibrillation–Subanalysis of the J-RHYTHM Registry–
JP2018538367A5 (es)
Palardy et al. Right ventricular dysfunction during intensive pharmacologic unloading persists after mechanical unloading
Cui et al. Pharmacologic approaches to weaning from cardiopulmonary bypass and extracorporeal membrane oxygenation
Sommer et al. Temporary circulatory support with surgically implanted microaxial pumps in postcardiotomy cardiogenic shock following coronary artery bypass surgery
CO2022000117A2 (es) Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida
Boffini et al. Role of oral sildenafil in the treatment of right ventricular dysfunction after heart transplantation
Park Efficacy of pulmonary vasodilator therapy in patients with functionally single ventricle
Mehmood et al. Treatment of right heart failure: is there a solution to the problem
AR085942A1 (es) Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
JP6839097B2 (ja) 医薬
Rajagopalan et al. Successful ventricular assist device placement in transposition of the great arteries with pulmonary hypertension
Alkhawam et al. Right ventricular failure following placement of a percutaneous left ventricular assist device
Sag et al. Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension
Rabanal et al. Perioperative management of pulmonary hypertension during lung transplantation (a lesson for other anaesthesia settings)
Ereminienė et al. Impact of advanced medical therapy for the outcome of an adult patient with Eisenmenger syndrome
Ammirati et al. Left ventricular or Bi-ventricular assist device? How dobutamine stress echocardiography can untie the dilemma of right ventricular dysfunction
Manda et al. INFLUENCE OF PREHYPERTENSION AND STAGE-1 HYPERTENSION ON THE OUTCOME OF ADULTS WITH HYPERTROPHIC CARDIOMYOPATHY
Jakuška et al. Left ventricular assist device with concominant tricuspid valve repair: Impact on right ventricular reverse remodelling and survival